{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:08:53Z","timestamp":1790683733351,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e482s","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:51:58Z","timestamp":1539683518000},"page":"e482s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"S1","title":["Marine drugs for cancer: surfacing biotechnological innovations from the oceans"],"prefix":"10.1016","volume":"73","author":[{"given":"Paula Christine","family":"Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Veras","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Veras","family":"Costa-Lotufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2018\/e482s_bib1","author":"National Cancer Institute"},{"key":"10.6061\/clinics\/2018\/e482s_bib2","author":"World Health Organization (WHO)"},{"issue":"23-24","key":"10.6061\/clinics\/2018\/e482s_bib3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.drudis.2009.09.006","article-title":"Anticancer drug discovery in the future: an evolutionary perspective","volume":"14","author":"Ma","year":"2009","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.6061\/clinics\/2018\/e482s_bib4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two- targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.6061\/clinics\/2018\/e482s_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression-implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"7210","key":"10.6061\/clinics\/2018\/e482s_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/455148a","article-title":"Cancer complexity slows quest for cure","volume":"455","author":"Check Hayden","year":"2008","journal-title":"Nature"},{"key":"10.6061\/clinics\/2018\/e482s_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/214186","article-title":"Anticancer drugs from marine flora: an overview","volume":"2010","author":"Sithranga Boopathy","year":"2010","journal-title":"J Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/np100550t","article-title":"Modern natural products drug discovery and its relevance to biodiversity conservation","volume":"74","author":"Kingston","year":"2011","journal-title":"J Nat Prod"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural Products as Sources of New Drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J Nat Prod"},{"key":"10.6061\/clinics\/2018\/e482s_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1590\/S0100-40422009000300014","article-title":"Organismos marinhos como fonte de novos f\u00e1rmacos: hist\u00f3rico e perspectivas","volume":"32","author":"Costa-Lotufo","year":"2009","journal-title":"Quim Nova"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib11","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1021\/cr900019j","article-title":"Impact of natural products on developing new anti-cancer agents","volume":"109","author":"Cragg","year":"2009","journal-title":"Chem Rev"},{"issue":"7019","key":"10.6061\/clinics\/2018\/e482s_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature03194","article-title":"Lessons from natural molecules","volume":"432","author":"Clardy","year":"2004","journal-title":"Nature"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1039\/b909989c","article-title":"Natural product mode of action (MOA) studies: a link between natural and synthetic worlds","volume":"27","author":"La Clair","year":"2010","journal-title":"Nat Prod Rep"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/cb100105c","article-title":"Natural products as chemical probes","volume":"5","author":"Carlson","year":"2010","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/np3006875","article-title":"Development of a natural products database from the biodiversity of Brazil","volume":"76","author":"Valli","year":"2013","journal-title":"J Nat Prod"},{"issue":"9-10","key":"10.6061\/clinics\/2018\/e482s_bib16","first-page":"775","article-title":"Drugs and Drug Candidates from Marine Sources: Na Assessment of the Current \u201cState of Play\u201d","volume":"82","author":"Newman","year":"2016","journal-title":"Planta Med"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/np5000796","article-title":"New horizons for old drugs and drug leads","volume":"77","author":"Cragg","year":"2014","journal-title":"J Nat Prod"},{"issue":"1","key":"10.6061\/clinics\/2018\/e482s_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chembiol.2011.12.014","article-title":"Lessons from the past and charting the future of marine natural products drug discovery and chemical biology","volume":"19","author":"Gerwick","year":"2012","journal-title":"Chem Biol"},{"key":"10.6061\/clinics\/2018\/e482s_bib19","author":"Mayer"},{"issue":"12","key":"10.6061\/clinics\/2018\/e482s_bib20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4155\/fmc.11.118","article-title":"Marine natural products: a new wave of drugs?","volume":"3","author":"Montaser","year":"2011","journal-title":"Future Med Chem"},{"issue":"5","key":"10.6061\/clinics\/2018\/e482s_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biotechadv.2011.03.001","article-title":"Bio-mining the microbial treasures of the ocean: new natural products","volume":"29","author":"Imhoff","year":"2011","journal-title":"Biotechnol Adv"},{"key":"10.6061\/clinics\/2018\/e482s_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/jo01201a011","article-title":"Contributions to the study of marine products. The Occurrence of Cetyl Palmitate in Corals","volume":"6","author":"Lester","year":"1941","journal-title":"J Org Chem"},{"issue":"6","key":"10.6061\/clinics\/2018\/e482s_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/jo01146a023","article-title":"Contributions to the study of marine products. The nucleosides of sponges","volume":"16","author":"Bergmann","year":"1951","journal-title":"J Org Chem"},{"issue":"11","key":"10.6061\/clinics\/2018\/e482s_bib24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/jo01128a007","article-title":"Contributions to the study of marine products. The nucleosides of sponges. III. Spongothymidine and spongouridine","volume":"20","author":"Bergmann","year":"1955","journal-title":"J Org Chem"},{"issue":"2","key":"10.6061\/clinics\/2018\/e482s_bib25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/jo01108a020","article-title":"Contributions to the study of marine products. The nucleosides of sponges. IV. Spongosine","volume":"21","author":"Bergmann","year":"1956","journal-title":"J Org Chem"},{"key":"10.6061\/clinics\/2018\/e482s_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1021\/jo01363a009","article-title":"Contributions to the study of marine products. The nucleosides of sponges. V. The synthesis of spongosine","volume":"22","author":"Bergmann","year":"1957","journal-title":"J Org Chem"},{"key":"10.6061\/clinics\/2018\/e482s_bib27","series-title":"Basic & clinical pharmacology","author":"Katzung","year":"2014"},{"issue":"10","key":"10.6061\/clinics\/2018\/e482s_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/np970181r","article-title":"Laurencia rigida: chemical investigations of its antifouling dichloromethane extract","volume":"60","author":"K\u00f6nig","year":"1997","journal-title":"J Nat Prod"},{"issue":"4","key":"10.6061\/clinics\/2018\/e482s_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(00)00292-8","article-title":"Marine organisms as a source of new anticancer agents","volume":"2","author":"Schwartsmann","year":"2001","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e482s_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"10.6061\/clinics\/2018\/e482s_bib31","series-title":"Food-drugs from the sea: proceedings 1969","first-page":"281","article-title":"Anti-cellular and antitumor activity of extracts from tropical marine invertebrates","author":"Sigel","year":"1970"},{"issue":"15","key":"10.6061\/clinics\/2018\/e482s_bib32","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","article-title":"Ecteinascidins 729, 743, 745, 759 A, 759B and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata","volume":"55","author":"Rinehart","year":"1990","journal-title":"J Org Chem"},{"issue":"15","key":"10.6061\/clinics\/2018\/e482s_bib33","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/jo00302a006","article-title":"Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata","volume":"55","author":"Wright","year":"1990","journal-title":"J Org Chem"},{"issue":"41","key":"10.6061\/clinics\/2018\/e482s_bib34","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"issue":"14","key":"10.6061\/clinics\/2018\/e482s_bib35","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/jm990241l","article-title":"Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove","volume":"42","author":"Zewail-Foote","year":"1999","journal-title":"J Med Chem"},{"issue":"1","key":"10.6061\/clinics\/2018\/e482s_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.6061\/clinics\/2018\/e482s_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0304-3835(95)04036-6","article-title":"The antitumoral compound Kahalalide F acts on cell lysosomes","volume":"99","author":"Garc\u00eda-Rocha","year":"1996","journal-title":"Cancer Lett"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib38","first-page":"179","article-title":"Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"issue":"12","key":"10.6061\/clinics\/2018\/e482s_bib39","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1073\/pnas.97.12.6775","article-title":"Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation","volume":"97","author":"Jin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.6061\/clinics\/2018\/e482s_bib40","first-page":"1327","article-title":"Overcoming multidrug drug resistance in P-glycoprotein\/MDR1 overexpressing cell lines by ecteinascidin 743","volume":"1","author":"Kanzaki","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.6061\/clinics\/2018\/e482s_bib41","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1073\/pnas.97.12.6780","article-title":"Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743","volume":"97","author":"Minuzzo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.6061\/clinics\/2018\/e482s_bib42","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.chembiol.2011.06.007","article-title":"XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids","volume":"18","author":"Feuerhahn","year":"2011","journal-title":"Chem Biol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e482s_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2014.149","article-title":"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment","volume":"111","author":"D'Incalci","year":"2014","journal-title":"Br J Cancer"},{"issue":"38","key":"10.6061\/clinics\/2018\/e482s_bib44","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1021\/ja962480t","article-title":"Enantioselective Total Synthesis of Ecteinascidin 743","volume":"118","author":"Corey","year":"1996","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Nat Prod Rep"},{"issue":"16","key":"10.6061\/clinics\/2018\/e482s_bib46","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1021\/ol0062502","article-title":"Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B","volume":"2","author":"Cuevas","year":"2000","journal-title":"Org Lett"},{"issue":"5","key":"10.6061\/clinics\/2018\/e482s_bib47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins - antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl Chem"},{"issue":"8","key":"10.6061\/clinics\/2018\/e482s_bib48","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1021\/ja00034a086","article-title":"Total synthesis of halichondrin B and nor- halichondrin B","volume":"114","author":"Aicher","year":"1992","journal-title":"J Am Chem Soc"},{"key":"10.6061\/clinics\/2018\/e482s_bib49","series-title":"Anticancer agents from natural products","first-page":"241","article-title":"Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B","author":"Yu","year":"2005"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib50","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"10.6061\/clinics\/2018\/e482s_bib51","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1021\/ja00256a070","article-title":"The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10","volume":"109","author":"Pettit","year":"1987","journal-title":"J Am Chem Soc"},{"key":"10.6061\/clinics\/2018\/e482s_bib52","series-title":"Fortschritte der Chemie Organischer Naturstoffe; Progress in the Chemistry of Organic Natural Products","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-7091-6551-5_1","article-title":"The dolastatins","author":"Pettit","year":"1997"},{"issue":"11","key":"10.6061\/clinics\/2018\/e482s_bib53","first-page":"4205","article-title":"Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma","volume":"6","author":"Vaishampayan","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-005-6735-y","article-title":"Phase II trial of dolastatin-10 in patients with advanced breast cancer","volume":"23","author":"Perez","year":"2005","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e482s_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e482s_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/19420862.2015.1082019","article-title":"Antibody-drug conjugates: Intellectual property considerations","volume":"7","author":"Storz","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"10.6061\/clinics\/2018\/e482s_bib58","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.3390\/md15040099","article-title":"Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates","volume":"15","author":"Newman","year":"2017","journal-title":"Mar Drugs"},{"issue":"8","key":"10.6061\/clinics\/2018\/e482s_bib59","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/cbdv.201000161","article-title":"Guanidine alkaloids from Monanchora arbuscula: chemistry and antitumor potential","volume":"8","author":"Ferreira","year":"2011","journal-title":"Chem Biodivers"},{"issue":"8","key":"10.6061\/clinics\/2018\/e482s_bib60","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1590\/S0103-50532009000800010","article-title":"Cytotoxic lipidic \u03b1-amino acids from the zoanthid Protopalythoa variabilis from the Northeastern coast of Brazil","volume":"20","author":"Wilke","year":"2009","journal-title":"J Braz Chem Soc"},{"issue":"22","key":"10.6061\/clinics\/2018\/e482s_bib61","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.1016\/j.bmc.2010.09.027","article-title":"Pro-apoptotic activity of lipidic \u03b1-amino acids isolated from Protopalythoa variabilis","volume":"18","author":"Wilke","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.6061\/clinics\/2018\/e482s_bib62","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/md10051092","article-title":"Structure elucidation and anticancer activity of 7-oxostaurosporine derivatives from the Brazilian endemic tunicate Eudistoma vannamei","volume":"10","author":"Jimenez","year":"2012","journal-title":"Mar Drugs"},{"issue":"4","key":"10.6061\/clinics\/2018\/e482s_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/cbic.201300717","article-title":"Identification of pyrroloformamide as a cytokinesis modulator","volume":"15","author":"Abreu","year":"2014","journal-title":"Chembiochem"},{"issue":"3","key":"10.6061\/clinics\/2018\/e482s_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/np200795p","article-title":"Anthracyclinones from Micromonospora sp","volume":"75","author":"Sousa","year":"2012","journal-title":"J Nat Prod"},{"issue":"2","key":"10.6061\/clinics\/2018\/e482s_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cbdv.201100092","article-title":"Studies on the secondary metabolites of a Pseudoalteromonas sp. isolated from sediments collected at the northeastern coast of Brazil","volume":"9","author":"Arthaud","year":"2012","journal-title":"Chem Biodivers"},{"issue":"S2","key":"10.6061\/clinics\/2018\/e482s_bib66","first-page":"335","article-title":"Cytotoxicity of actinomycetes associated with the ascidian Eudistoma vannamei (Millar, 1977), endemic of northeastern coast of Brazil","volume":"41","author":"Jimenez","year":"2013","journal-title":"Lat Am J Aquat Res"},{"issue":"12","key":"10.6061\/clinics\/2018\/e482s_bib67","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.3390\/md12125839","article-title":"Chromomycin A2 induces autophagy in melanoma cells","volume":"12","author":"Guimar\u00e3es","year":"2014","journal-title":"Mar Drugs"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:01:40Z","timestamp":1761721300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011279"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200310&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/improving-adenoviral-vectors-and-strategies-for-prostate-cancer-gene-therapy\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":67,"alternative-id":["S1807593222011279"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e482s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marine drugs for cancer: surfacing biotechnological innovations from the oceans","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e482s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e482s"}}